title: Anti-neuroinflammatory and neurotrophic effects of combined therapy with annexin II and Reg-2 on injured spinal cord.
abstract: The present study was designed to investigate the neuroprotective effects of Ca(2+)-dependent phospholipid-binding protein annexin II and a secreted protein Reg-2 (regeneration gene protein 2) in spinal cord injury (SCI) model produced by contusion SCI at T(9) using the weight drop method. The agents were delivered intrathecally with Alzet miniosmotic pumps. We found that annexin II and Reg-2 remarkably reduced neuronal death, attenuated tissue damage and alleviated detrimental inflammation in vivo; meanwhile, a significant increase in white matter sparing and myelination area was observed. The propriospinal axons and long-distance supraspinal pathways were protected by the treatments as revealed by retrograde tracing. Basso Beattie Bresnahan locomotor rating scores also revealed a measurable behavioral improvement. However, no evident behavioral improvements in locomotor performance were achieved by the combined treatment with annexin II and Reg-2, compared with the separate treatment with annexin II and Reg-2.
authors: Institute of Anatomy and Cell Biology, Medical College, Zhejiang University, Hangzhou, China.
authors: Marong
authors: M
authors: Fang
authors: Jian-Ying
authors: JY
authors: Huang
authors: Jing
authors: J
authors: Wang
authors: Shu-Cai
authors: SC
authors: Ling
authors: John A
authors: JA
authors: Rudd
authors: Zhi-Ying
authors: ZY
authors: Hu
authors: Lin-Hao
authors: LH
authors: Xu
authors: Zhang-Gen
authors: ZG
authors: Yuan
authors: Shu
authors: S
authors: Han
mesh_terms: D000818:Animals; D017306:Annexin A2 / Q000627:therapeutic use*; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D015703:Antigens, CD / Q000378:metabolism; D004195:Disease Models, Animal; D004359:Drug Therapy, Combination / Q000379:methods; D005260:Female; D019922:GAP-43 Protein / Q000378:metabolism; D005786:Gene Expression Regulation / Q000187:drug effects; D005904:Glial Fibrillary Acidic Protein / Q000378:metabolism; D016179:Granulocyte Colony-Stimulating Factor / Q000378:metabolism; D007377:Interleukin-3 / Q000378:metabolism; D051847:Lithostathine / Q000627:therapeutic use*; D008124:Locomotion / Q000187:drug effects; D009414:Nerve Growth Factors / Q000627:therapeutic use*; D016900:Neurofilament Proteins / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D011993:Recombinant Fusion Proteins / Q000378:metabolism; D011994:Recombinant Proteins; D013119:Spinal Cord Injuries / Q000188:drug therapy* / Q000503:physiopathology; D013266:Stilbamidines
chemical_list: C049774:2-hydroxy-4,4'-diamidinostilbene, methanesulfonate salt; D017306:Annexin A2; D000893:Anti-Inflammatory Agents; D015703:Antigens, CD; D019922:GAP-43 Protein; D005904:Glial Fibrillary Acidic Protein; D007377:Interleukin-3; D051847:Lithostathine; D009414:Nerve Growth Factors; D016900:Neurofilament Proteins; D011993:Recombinant Fusion Proteins; D011994:Recombinant Proteins; C497616:Reg1a protein, rat; D013266:Stilbamidines; C404145:myelopoietin; C061195:neurofilament protein M; D016179:Granulocyte Colony-Stimulating Factor